article thumbnail

Growth Perspectives: Key Highlights from DCAT 2024

Frost & Sullivan

Growth Opportunity 2 – Medical Cannabidiol (CBD) Global regulatory shifts toward legalizing medical cannabis and CBD products highlight the growing interest in cannabis-based treatments. Partnerships with specialty CDMOs experienced in manufacturing schedule 1 products can accelerate clinical trials and R&D.